Detalhe da pesquisa
1.
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Clin Infect Dis
; 73(8): 1346-1354, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33830182
2.
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer
; 127(10): 1598-1605, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33471943
3.
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.
Genome Res
; 28(4): 432-447, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567676
4.
Ab initio spillover compensation in mass cytometry data.
Cytometry A
; 99(9): 899-909, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33342071
5.
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.
Acta Haematol
; 144(1): 74-81, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32604096
6.
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Cancer
; 126(10): 2183-2192, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32101640
7.
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
Cancer
; 126(10): 2193-2205, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125707
8.
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.
Blood
; 131(11): 1248-1257, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386198
9.
The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
J Infect Dis
; 219(6): 898-907, 2019 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30295846
10.
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
Biol Blood Marrow Transplant
; 24(7): 1514-1520, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29448058
11.
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
Biol Blood Marrow Transplant
; 23(8): 1359-1366, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28506845
12.
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Cancer
; 123(14): 2661-2670, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28324640
13.
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Br J Haematol
; 177(3): 457-466, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28295190
14.
Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.
Blood
; 125(9): 1502-6, 2015 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428215
15.
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Haematologica
; 102(1): 110-117, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27540139
16.
Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
J Infect Dis
; 213(11): 1701-7, 2016 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26908740
17.
Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.
Am J Hematol
; 96(9): E350-E353, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096089
18.
Chimeric antigen receptor natural killer cells for the treatment of patients with B-cell malignancies.
Clin Adv Hematol Oncol
; 18(9): 543-545, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33006583
19.
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Blood
; 119(21): 5030-6, 2012 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22371885
20.
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
Cytotherapy
; 16(1): 90-100, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24480547